Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non–small-cell lung cancer and a performance status of 2
R Lilenbaum, R Axelrod, S Thomas… - Journal of Clinical …, 2008 - ascopubs.org
… the efficacy of erlotinib and standard chemotherapy in the PS 2 … dose of erlotinib or standard
chemotherapy were considered … with chemotherapy were allowed to cross over to erlotinib …
chemotherapy were considered … with chemotherapy were allowed to cross over to erlotinib …
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a …
R Rosell, E Carcereny, R Gervais… - The lancet …, 2012 - thelancet.com
… Erlotinib has been shown to improve progression-free survival compared with chemotherapy
when … the safety and efficacy of erlotinib compared with standard chemotherapy for first-line …
when … the safety and efficacy of erlotinib compared with standard chemotherapy for first-line …
Erlotinib (Tarceva): an update on the clinical trial program
RS Herbst - Seminars in oncology, 2003 - Elsevier
… Lung Cancer Investigation), were designed to examine erlotinib in combination with
standard chemotherapeutic agents as first-line therapy for patients with advanced NSCLC. The …
standard chemotherapeutic agents as first-line therapy for patients with advanced NSCLC. The …
Chemotherapy with erlotinib or chemotherapy alone in advanced non‐small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors
SB Goldberg, GR Oxnard, S Digumarthy… - The …, 2013 - academic.oup.com
… with chemotherapy plus erlotinib rather than chemotherapy alone … We found that continuing
erlotinib with chemotherapy … prospective trial comparing chemotherapy with erlotinib and …
erlotinib with chemotherapy … prospective trial comparing chemotherapy with erlotinib and …
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non–small-cell lung cancer
… of erlotinib and chemotherapy improves clinical outcomes versus chemotherapy alone in
unselected, chemotherapy-naïve … phase III trials. In these studies, concurrent administration of …
unselected, chemotherapy-naïve … phase III trials. In these studies, concurrent administration of …
… NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials
… We concluded that the erlotinib plus chemotherapy for … that erlotinib combined with
platinum-based chemotherapy was … compared with platinum-based chemotherapy alone regime. …
platinum-based chemotherapy was … compared with platinum-based chemotherapy alone regime. …
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a …
T Ciuleanu, L Stelmakh, S Cicenas, S Miliauskas… - The lancet …, 2012 - thelancet.com
… tolerability of erlotinib compared with standard chemotherapy (… -line, platinum-doublet
chemotherapy. We also investigated … This prospective head-to-head trial was designed to assess …
chemotherapy. We also investigated … This prospective head-to-head trial was designed to assess …
Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
T Mitsudomi - The Lancet Oncology, 2011 - thelancet.com
… in the Asian population, never-smokers, women, and patients with adenocarcinoma led
to the first phase 3 trial comparing an EGFR TKI with chemotherapy in the first-line setting. …
to the first phase 3 trial comparing an EGFR TKI with chemotherapy in the first-line setting. …
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - The lancet …, 2011 - thelancet.com
… We do not believe that there is a need to a head-to-head clinical trial between gefinitib
and erlotinib; rather, further investigation is needed into why responding patients develop …
and erlotinib; rather, further investigation is needed into why responding patients develop …
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancer
RS Herbst, D Prager, R Hermann… - Journal of clinical …, 2005 - ascopubs.org
… This is a report of a phase III trial that evaluated whether concurrent administration of erlotinib
with standard chemotherapy could enhance survival in chemotherapy-naïve patients with …
with standard chemotherapy could enhance survival in chemotherapy-naïve patients with …
相关搜索
- standard chemotherapy lung cancer
- phase iii trial of erlotinib
- randomized trials erlotinib in patients
- chemotherapy with erlotinib acquired resistance
- clinical trial program erlotinib tarceva
- paclitaxel chemotherapy erlotinib hydrochloride
- conventional chemotherapy efficacy of erlotinib
- first line erlotinib phase 3 trial
- clinical trial design erlotinib or gefitinib
- standard chemotherapy randomised phase 3 trial
- trial of erlotinib performance status
- standard chemotherapy multicentre open label
- standard chemotherapy european patients
- trial of erlotinib randomized phase
- standard chemotherapy first line treatment
- standard chemotherapy small cell lung cancer